Divi's Laboratories Q2 FY26 Earnings Results: 35% YoY PAT Growth; Share Price in Focus

Divi's Laboratories Limited announced its consolidated unaudited financial results for the quarter and half-year ended September 30, 2025. The pharmaceutical company reported robust growth across all key financial metrics on a year-on-year, quarter-on-quarter, and half-yearly basis.

Divi's Laboratories Q2 FY26 Earnings Results

For the quarter ended September 30, 2025, Divi's Laboratories achieved consolidated total income of ₹2,860 crore, registering growth of 17% YoY and 13% QoQ. Revenue from operations stood at ₹2,715 crore, surging 27% YoY and 13% QoQ compared to the respective periods.

Profit before tax reached ₹912 crore, marking a 26% increase YoY and 24% growth QoQ. Profit after tax stood at ₹689 crore, demonstrating strong expansion of 35% YoY and 26% QoQ. Basic and diluted earnings per share were ₹25.97 for the quarter.

Divi's Laboratories Half-Year FY26 Earnings Results

For the half year ended September 30, 2025, consolidated total income reached ₹5,389 crore, up 16% compared to ₹4,640 crore in H1 FY25. Revenue from operations totalled ₹5,125 crore, reflecting a substantial 26% growth year on year.

Half-year PBT stood at ₹1,645 crore, growing 24% from ₹1,326 crore in the previous year. PAT for H1 FY26 came to ₹1,234 crore, up 31% from ₹940 crore in H1 FY25. Earnings per share for the half year were ₹46.46.

Read More: Alembic Pharmaceuticals Share Price Surges Over 7% as Q2 FY26 Revenue Jumps 16%, PAT Up 20%!

Expense and Forex Performance

Total expenses for Q2 FY26 amounted to ₹1,948 crore, with material costs at ₹937 crore and employee expenses at ₹354 crore. The company benefited from forex gains of ₹63 crore in Q2 FY26 compared to ₹29 crore in Q2 FY25.

Balance Sheet Highlights

As of September 30, 2025, consolidated total assets stood at ₹18,151 crore. Current assets totalled ₹9,843 crore, including inventories of ₹3,433 crore and trade receivables of ₹2,614 crore. Total equity was ₹15,413 crore with total liabilities at ₹2,738 crore.

Divi's Laboratories Share Price Performance

On November 7, 2025, Divi's Laboratories share price opened at ₹6,874.50 on NSE, below the previous close of ₹6,883.50. During the day, it surged to ₹6,892.00 and dipped to ₹6,620.50. The stock is trading at ₹6,699.00 as of 12:43 PM. The stock registered a significant decline of 2.68%.

Over the past week, it has declined by 1.54%, over the past month, it has moved up by 9.25%, and over the past 3 months, it has moved up by 9.26%.

Conclusion

Divi's Laboratories demonstrated exceptional consolidated performance in Q2 and H1 FY26 with PAT growing 35% YoY and revenue expanding 27% YoY, supported by operational efficiency and favourable forex movements.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.